Meet Our Board
We are committed to your study needs.
Our board of directors is composed of trusted industry professionals. Their leadership and oversight ensure we fulfill our mission to improve the way clinical research is performed.
Managing Director at Morgan Stanley Expansion Capital
Melissa Daniels is a managing director at Morgan Stanley Expansion Capital and the co-head and managing member of Morgan Stanley Venture Partners. She has been an active growth equity investor and board member in numerous software, health care service, health care IT, and medical device companies. Her current and recent board positions also include Arcadian Health, Discoverx, EKOS, IdeaS, National Healing, PeopleClick, and SouthernCare.
Prior to joining Morgan Stanley, Daniels held operational and management roles in private companies and served as staff on a subcommittee of the U.S. House of Representatives.
Partner at Petra Capital Partners
A partner at Petra Capital Partners, David Fitzgerald is also currently a director on the boards of Urgent Team, New Century Hospice, Opportune IT Healthcare Solutions, Access Media 3, SUN Behavioral Health, VirMedica, and Lineagen. Fitzgerald has broad experience in both private equity and mergers and acquisitions. His primary focus has been on the health care, information technology, and business services sectors.
Prior to joining Petra, Fitzgerald was a general partner at Richland Ventures. Earlier in his career, he led market development and acquisition activities for InformDx, a diagnostic laboratory company, and THG Management Services, a managed health care company.
Principal, Private Equity Investments for Mario Family Partners
Jeremy Mario serves as principal of private equity investments for Mario Family Partners and has more than 10 years experience in the pharmaceutical and health care fields, ranging from clinical development services to marketing and research. For the past nine years, he has managed the private equity portfolio of Mario Family Partners, a diversified asset management company that specializes in early stage biotech ventures.
Mario has extensive expertise in helping early stage companies refine business plans and capitalization goals.
Principal, EXPIS Partners
Steve Skolsky is principal of EXPIS Partners, a biopharmaceutical and life science consultancy. He serves on the board of directors at Basilea Pharmaceutica, a Swiss-based biotech company, on the Foundation Board of University of North Carolina-Chapel Hill’s Kenan Flagler Business School, and on the Board of Visitors of UNC-Chapel Hill.
A recognized health care and life science leader with more than 30 years of industry experience, Skolsky has extensive general management and international life science sector experience with emphasis on product strategy, commercialization, and product development. He has held senior executive leadership positions in pharmaceutical, biotechnology, and health care services including CEO/president roles in both private and public sectors.
Managing Partner and Chief Investment Officer at Virgo
Jesse Watson co-founded Virgo with Capricorn Investment Group as the initial, anchor investor. He is currently the managing partner and chief investment officer with lead responsibility for the day-to-day operations, the fund, the sourcing and investment process, portfolio construction, and investor relationships.
Prior to Virgo, Watson was a senior investment professional at Eton Park Capital Management, a portfolio manager with R6 Capital Management, a senior investment professional at Silver Point Capital, an associate with Clayton, Dubilier and Rice (CD&R), and an analyst with Morgan Stanley Capital Partners, the leveraged buyout principal investment division of Morgan Stanley.
Partner at Crestline
Chris Semple, managing director, joined Crestline in 2011 and is responsible for Crestline’s opportunistic and private credit strategies. He also currently serves on the board of directors of Carepayment Technologies, Leading Pharma, and Urgent Team Holdings, and he is a member of YPO.
Prior to Crestline, Semple was vice president in the Special Situations Group for Goldman Sachs where he was responsible for originating, underwriting, executing, and managing middle market debt and equity investment opportunities. Semple also worked as a credit analyst within the Special Opportunities Group for TQA Investors, focusing on liquid credits as well as managing a long-only convertible bond fund.
CEO at Clinipace
Jason Monteleone joined Clinipace in October 2017. He accepted the role of CEO after spending several months of strategic consulting with Clinipace.
Prior to Clinipace, Monteleone founded Pivotal Financial Consulting LLC, was executive vice president and chief financial officer of Theorem Clinical Research, was chief financial officer of Omnicare Clinical Research, and held executive finance positions at MDS Pharma Services and VIASYS Healthcare.